Insulin

World's largest insulin manufacturer. Controls ~33.7% of global diabetes care market; ~45% of human insulin. Operates the world's largest insulin production facility in Kalundborg, Denmark (produces ~50% of global insulin supply). Dominant in GLP-1 drugs (Ozempic/Wegovy); FY2024 revenue DKK 232B. Uses both E. coli and yeast fermentation.

Life sciences tools company (Marlborough, MA; wholly-owned by Danaher Corporation since $21.4B acquisition of GE Healthcare Life Sciences in 2020) that manufactures Whatman membrane filter papers and sterile filtration products alongside its dominant chromatography resin (Capto, Sephadex, Sepharose series) and bioreactor (WAVE, XDR) platforms. Cytiva is the successor to GE Healthcare Life Sciences and Amersham Biosciences. Whatman-branded products include nitrocellulose and mixed cellulose ester membranes used in sterile filtration, diagnostics, and laboratory applications. Cytiva's role in sterile filtration is secondary to Merck KGaA and Pall — Whatman filters are more prevalent in laboratory/QC applications than primary pharmaceutical manufacturing sterilization — but Cytiva's ownership alongside Pall within Danaher creates the world's most concentrated supply position in biopharmaceutical manufacturing consumables. Danaher's combined Pall + Cytiva platform spans filtration, chromatography, bioreactors, and cell culture media — covering essentially every critical consumable step in a biologics manufacturing process.

Second-largest insulin manufacturer; invented the first commercial insulin (1923). Uses Saccharomyces cerevisiae (yeast) fermentation exclusively. Markets Humalog (lispro), Basaglar (glargine), and Lyumjev. Also dominant in GLP-1 market (Mounjaro/Zepbound). FY2024 revenue ~$45B.

Third of the global insulin oligopoly. Markets Lantus (glargine) — historically the world's best-selling insulin — and Toujeo. Uses E. coli fermentation at Frankfurt plant. WHO-prequalified for insulin glargine. Divesting insulin business in some regions as GLP-1 market grows.

German science company (Darmstadt; family-owned since 1668) life sciences division (MilliporeSigma in US) produces Fractogel EMD bioprocess chromatography resins alongside its Millipore filtration products and Sigma-Aldrich research chemicals. Fractogel resins (Fractogel EMD SO3-, Fractogel EMD TMAE) are an alternative to Cytiva's Capto resins for cation and anion exchange steps in biologics purification — primarily used by biomanufacturers seeking to reduce single-supplier dependence on Cytiva. Merck KGaA's same Darmstadt facility that makes sterilizing filters for pharmaceutical manufacturers (Durapore, Millipak) also produces the Fractogel resins used in the same manufacturers' upstream purification trains.

Japanese bioscience and chromatography subsidiary of Tosoh Corporation (TYO: 4042, HQ Tokyo; ~¥900B revenue); produces TOYOPEARL brand bioprocess chromatography resins — the primary alternative to Cytiva resins for protein A (Protein A resin for antibody purification), hydrophobic interaction, and ion exchange chromatography in biologics manufacturing. Tosoh Bioscience's Protein A resins (TOYOPEARL AF-rProtein A and similar) are validated alternatives to Cytiva's MabSelect series for monoclonal antibody purification — one of the few Cytiva process alternatives with sufficient regulatory documentation for biologics manufacturers to qualify. Tosoh Corporation also manufactures specialty vinyl chloride resins, chlor-alkali chemicals, and other industrial chemicals alongside its bioscience chromatography business — a Japanese conglomerate spanning plastic pipes, caustic soda, and biologics purification from one Tokyo industrial company.

Intas Pharmaceuticals (Ahmedabad Gujarat India; privately held; founded 1976 by Hasmukh Chudgar; ~$2.4B revenue est. 2022) is the world's largest manufacturer of cisplatin and carboplatin APIs and one of India's largest private pharmaceutical companies. Intas operates its international generic injectable business under the brand Accord Healthcare (UK-registered subsidiary). Intas's Ahmedabad/Sanand API manufacturing complex in Gujarat was the single most important source of cisplatin API for the US market, supplying an estimated 50-60% of US cisplatin imports from its Gujarat facilities. In November 2022, FDA investigators conducting a pre-approval inspection at Intas's Ahmedabad manufacturing facility (FEI 3003889748) discovered hundreds of trash bags filled with shredded quality-control documents — evidence of deliberate document destruction intended to conceal data integrity violations. FDA issued a Form 483 with 10 observations. The FDA subsequently issued a Warning Letter in December 2022. Intas voluntarily ceased API production at the facility. The resulting API supply gap triggered the worst US oncology drug shortage in a decade, beginning in February 2023 for cisplatin and April 2023 for carboplatin. The Intas-Accord shortage became the central case study for pharmaceutical supply chain concentration risk.

Indian biotechnology and pharmaceutical company (NSE: BIOCON; Biocon Biologics listed separately; HQ Bangalore; ~₹150B revenue for Biocon group); Biocon is India's largest biopharmaceutical company and a major producer of complex small molecules and biologics including cyclosporine A API and immunosuppressants. Biocon Limited was founded in 1978 by Kiran Mazumdar-Shaw — one of India's most prominent female entrepreneurs — as an enzyme fermentation company, starting in a garage with ₹10,000 in capital. Today Biocon is a ~$3B revenue pharmaceutical company producing insulin biosimilars, cancer biologics, and complex small molecule APIs including cyclosporine A. The same Biocon that produces the cyclosporine A API for generic dry eye drops also produces trastuzumab biosimilar (Herceptin equivalent for breast cancer) and insulin analogs for diabetes — one Indian startup from 1978 spanning oncology, endocrinology, and ophthalmology API supply chains.